It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

1 Early and rapid identification of COVID-19 patients with neutralizing type I-interferon

2 auto-antibodies by an easily implementable algorithm

3

4 Bengisu Akbil^{1,2}*, Tim Mever³*, Paula Stubbemann⁴*, Charlotte Thibeault⁴*, Olga Staudacher^{3,5}, Daniela Niemeyer^{1,6}, Jenny Jansen^{1,2}, Barbara Mühlemann^{1,6}, Jan Doehn⁴, 5 6 Christoph Tabeling^{2,4}, Christian Nusshag⁷, Cédric Hirzel⁸, David Sökler Sanchez^{9,10}, 7 Alexandra Nieters^{11,} Achim Lother¹², Daniel Duerschmied¹², Nils Schallner^{13,14}, Jan Nikolaus 8 Lieberum^{13,14}, Dietrich August¹⁵, Siegbert Rieg¹⁵, Valeria Falcone¹⁶, Hartmut Hengel¹⁶, Uwe Kölsch³, Nadine Unterwalder³, Ralf-Harto Hübner^{2,4}, Terry C. Jones^{1,6,17}, Norbert Suttorp⁴, 9 10 Christian Drosten^{1,6}, Klaus Warnatz^{9,10}, Thibaud Spinetti¹⁸, Joerg C. Schefold¹⁸, Thomas Dörner¹⁹, Leif Sander⁴, Victor M. Corman^{1,6,20}, Uta Merle²¹, Pa-COVID study Group²², Florian 11 Kurth^{4,23#}, Horst von Bernuth^{2,3,5,24#}, Christian Meisel^{3,25#}, Christine Goffinet^{1,2#} 12 13 14 ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and 15 Humboldt-Universität zu Berlin, Institute of Virology, 10117 Berlin, Germany 16 ²Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany 17 ³Labor Berlin GmbH, Department of Immunology, Berlin, Germany 18 ⁴Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and 19 Humboldt-Universität zu Berlin, Department of Infectious Diseases and Respiratory 20 Medicine, Berlin, Germany 21 ⁵Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, 22 Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric 23 Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany 24 ⁶DZIF German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, 25 Germany 26 ⁷Department of Nephrology, Heidelberg University Hospital, Heidelberg, Germany 27 ⁸Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, 28 Bern, Switzerland

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

- ⁹Department of Rheumatology and Clinical Immunology, Medical Center University of
- 30 Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
- 31 ¹⁰Center for Chronic Immunodeficiency (CCI), Medical Center University of Freiburg,
- 32 Faculty of Medicine, University of Freiburg, Freiburg, Germany
- ¹¹University Medical Center Freiburg and Faculty of Medicine, University of Freiburg, Center
- 34 for Biobanking, FREEZE-Biobank, Freiburg, Germany
- 35 ¹²Cardiology and Medical Intensive Care, Heart Center, Faculty of Medicine, University of
- 36 Freiburg
- ¹³Department of Anesthesiology and Critical Care, Medical Center University of Freiburg,
- 38 Germany
- ¹⁴Faculty of Medicine, University of Freiburg, Germany
- 40 ¹⁵Division of Infectious Diseases, Department of Medicine II, Medical Centre University of
- 41 Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany
- 42 ¹⁶Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, Albert-
- 43 Ludwigs-University of Freiburg, Freiburg, Germany.
- ¹⁷Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Downing
- 45 St., Cambridge, CB2 3EJ, U.K.
- ¹⁸Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of
- 47 Bern, Freiburgstrasse, CH-3010 Bern, Switzerland
- 48 ¹⁹Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and
- 49 Humboldt-Universität zu Berlin, Department of Medicine/Rheumatology and Clinical
- 50 Immunology, Berlin, Germany and DRFZ, Berlin, Germany
- ²⁰Labor Berlin GmbH, Berlin, Germany
- 52 ²¹ Department of Gastroenterology, Heidelberg University Hospital, Heidelberg, Germany
- 53 ²²Collaborators listed at the end of the article
- 54 ²³Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine and
- 55 Department of Medicine I, University Medical Centre Hamburg-Eppendorf, Hamburg,
- 56 Germany

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

57 ²⁴Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, 58 Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin-Brandenburg 59 Center for Regenerative Therapies (BCRT), Berlin, Germany ²⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and 60 61 Humboldt-Universität zu Berlin, Institute of Medical Immunology, Berlin, Germany 62 63 *These authors contributed equally *These authors contributed equally, co-corresponding authors 64 65 66 67 Corresponding authors: 68 Florian Kurth; Department of Infectious Diseases and Respiratory Medicine, Charité -69 Berlin, Augustenburger Universitätsmedizin Platz 1, D-13353 Berlin, Germany, 70 florian.kurth@charite.de, +49 30 450 665023 71 72 Horst von Bernuth; Department of Pediatric Respiratory Medicine, Immunology and Critical 73 Care Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, D-13353 74 Berlin, Germany, horst.von-bernuth@charite.de, +49 30 450 566693 75 76 Christian Meisel, Labor Berlin, Charité - Universitätsmedizin Berlin, Sylter Str. 2, 13353 77 Berlin, Germany, christian.meisel@laborberlin.com, +49 30 405026471 78 79 Christine Goffinet, Institute for Virology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 80 10117 Berlin, Germany, christine.goffinet@charite.de, +49 30 450525489 81 82 83 84 85

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

86 **ABSTRACT**

87

88 Purpose

Six-19% of critically ill COVID-19 patients display circulating auto-antibodies against type I
interferons (IFN-AABs). Here, we establish a clinically applicable strategy for early
identification of IFN-AAB-positive patients for potential subsequent clinical interventions.

92

93 Methods

We analysed sera of 430 COVID-19 patients with severe and critical disease from four hospitals for presence of IFN-AABs by ELISA. Binding specificity and neutralizing activity were evaluated via competition assay and virus-infection-based neutralization assay. We defined clinical parameters associated with IFN-AAB positivity. In a subgroup of critically ill patients, we analyzed effects of therapeutic plasma exchange (TPE) on the levels of IFN-AABs, SARS-CoV-2 antibodies and clinical outcome.

100

101 Results

102 The prevalence of neutralizing AABs to IFN- α and IFN- ω in COVID-19 patients was 4.2% 103 (18/430), while being undetectable in an uninfected control cohort. Neutralizing IFN-AABs 104 were detectable exclusively in critically affected, predominantly male (83%) patients (7.6% 105 IFN- α and 4.6% IFN- ω in 207 patients with critical COVID-19). IFN-AABs were present early 106 post-symptom onset and at the peak of disease. Fever and oxygen requirement at hospital 107 admission co-presented with neutralizing IFN-AAB positivity. IFN-AABs were associated with 108 higher mortality (92.3% versus 19.1 % in patients without IFN-AABs). TPE reduced levels of 109 IFN-AABs in three of five patients and may increase survival of IFN-AAB-positive patients 110 compared to those not undergoing TPE.

111

112

113

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

- 114 Conclusion
- 115 IFN-AABs may serve as early biomarker for development of severe COVID-19. We propose
- to implement routine screening of hospitalized COVID-19 patients according to our algorithm
- 117 for rapid identification of patients with IFN-AABs who most likely benefit from specific
- 118 therapies.
- 119
- 120 3-5 KEYWORDS
- 121 COVID-19, SARS-CoV-2, type I interferon, autoantibodies
- 122

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

123 INTRODUCTION

124 Since its first detection in Wuhan, China, in 2019, Severe-acute-respiratory syndrome 125 Coronavirus 2 (SARS-CoV-2) has placed an unprecedented burden on health care systems 126 worldwide. The clinical spectrum of the associated disease, COVID-19, ranges from 127 asymptomatic infection to severe disease with hypoxemia, acute respiratory distress 128 syndrome (ARDS), multiorgan failure, and death (Pfortmueller et al. 2021). Approximately 129 35% of patients remain asymptomatic, 55% develop upper respiratory tract infections, 130 whereas 15% develop severe pneumonia (defined as SpO2 < 90% at room air) and 5% 131 critical pneumonia (defined as Acute Respiratory Distress Syndrome (ARDS), requiring 132 mechanical ventilation or extra-corporeal membrane (ECMO) (Sah et al. 2021).

133 Scores containing clinical and laboratory parameters support risk stratification and 134 resource allocation in clinical practice worldwide (Knight et al. 2020; "Information on COVID-135 19 Treatment, Prevention and Research" n.d.). Demographic and clinical risk factors for a 136 severe disease course include advanced age, male sex, and pre-existing comorbidities 137 (Williamson et al. 2020). Moreover, genetic polymorphisms are associated with progression 138 to severe disease (COVID-19 Host Genetics Initiative 2021). Cell-intrinsic innate viral 139 sensors and antiviral cytokines, including type I and type III interferons (IFNs), orchestrate 140 the control of SARS-CoV-2 infection (Kim and Shin 2021). Inherited mutations of genes 141 involved in IFN induction and signalling and circulating auto-antibodies (AABs) that 142 neutralize type I IFNs have been found to predispose infected individuals to severe COVID-143 19 (Bastard et al. 2020; Zhang et al. 2020), presumably by contributing to an ineffective 144 immune response with delayed or abolished type I IFN signaling. Neutralizing type I IFN-145 AABs are present in 6-17% of hospitalized COVID-19 patients with severe pneumonia 146 (Bastard et al. 2020; Koning et al. 2021; Troya et al. 2021) and 11-19% in critically ill 147 COVID-19 patients (Bastard et al. 2020; van der Wijst et al. 2021; Goncalves et al. 2021), 148 greatly exceeding estimated prevalences of around 0.33% (Bastard et al. 2020) in uninfected 149 individuals. Intriguingly, while neutralizing IFN-AABs in patients with autoimmune 150 polyendocrine syndrome type 1 (APS-1) can associate with a severe course of SARS-CoV-2

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

151 infection (Bastard et al. 2021; Beccuti et al. 2020; Carpino et al. 2021; Ferré et al. 2021; 152 Lemarquis et al. 2021), their mere presence does not inevitably lead to severe disease 153 (Meisel et al. 2021). A recent global multi-cohort study reports prevalence of neutralizing 154 IFN-AABs in 4% of uninfected individuals over 70 years of age, suggesting that IFN-AABs 155 may pre-exist in some individuals that develop a critical course of COVID-19 (Bastard et al. 156 2021). Thus, we reasoned that IFN-AABs may serve as biomarkers that could, in conjunction 157 with other clinical parameters, help to predict risk for developing severe COVID-19 and to 158 stratify patients for specific therapies.

Specific therapies may comprise the administration of recombinant IFN-β or therapeutic plasma exchange (TPE). However, the clinical benefit of TPE and other approaches remains to be defined and requires studies involving large numbers of patients. With IFN-AABs present in up to 18% of deceased COVID-19 patients (Bastard et al. 2021) and given the limited therapeutic options for severely affected COVID-19 patients, testing specific therapeutic approaches is of high urgency, yet clinically implementable strategies for rapid and early identification of IFN-AAB-positive patients upfront are missing.

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

166 **METHODS**

167

168 Study cohorts and data collection

169 Patients were recruited and data and sample collection was performed within one of four 170 prospective observational studies conducted at Charité - Universitätsmedizin Berlin, 171 Germany (Cohort A, (Kurth et al. 2020)), Inselspital Universitätsspital Bern, Switzerland 172 (Cohort B), Universitätsklinikum Freiburg, Germany (Cohort C) and Universitätsklinikum 173 Heidelberg, Germany (Cohort D). For this analysis, all patients with a maximum WHO score 174 of 3-8 were included from Cohorts A-C (henceforth summarized as cross-sectional cohorts, 175 CSC). For cohort D (therapeutic plasma exchange cohort, TPEC) only patients who 176 underwent therapeutic plasma exchange for treatment of COVID-19-associated 177 hyperinflammatory syndrome at the Department of Internal Medicine IV of Heidelberg 178 University Hospital, Germany (Nusshag et al. 2021) and supplementary methods) were 179 retrospectively selected. All TPE procedures were performed in accordance with the German 180 Medical Devices Act ("Medizinproduktegesetz"). Healthy controls were recruited from a study 181 on SARS-CoV-2 exposition in health care workers (HC cohort). Samples from APS-1 182 patients were obtained from a published study (Meisel et al. 2021) and published values are 183 shown here for reference. All studies were conducted according to the Declaration of 184 Helsinki and Good Clinical Practice principles (ICH 1996).

185

186 Detection of IFN-AABs by reverse ELISA

187 IFN-AABs were detected using an electrochemiluminescence immunoassay (ECLIA)-188 platform (MSD, Rockville, U.S.), as described recently (Meisel et al. 2021). Briefly, MSD 189 GOLD 96-well small spot streptavidin SECTOR Plates (MSD) were washed with wash buffer 190 (MSD), and blocked with 150 µl blocking buffer (Thermo Fisher, Waltham, U.S.) per well at 191 4°C overnight. All further incubations were performed for 60 minutes at room temperature. 192 After blocking, plates were incubated with IFN-α2 (Merck Sharp & Dohme, Kenilworth, USA)

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

193	or IFN-((Peprotech, Rocky Hill, USA) linked to biotin (Thermo Scientific, Waltham, USA).
194	Next, plates were incubated with patients' sera following dilution at 1:100 in blocking buffer.
195	Cytokine AABs were detected using a monoclonal mouse antibody to human IgG (D20JL-6,
196	MSD). After incubation and washing, 150 μl of read buffer (ReadBufferT (4x), MSD) were
197	added, incubated for ten minutes at room temperature, and plates were analyzed using the
198	MESO QuickPlex SQ 120 analyzer (MSD). Data are shown as light signal counts (LSC).

199

200 Competition assays

201 All sera whose IFN-α2-AABs and/or IFN-ω-AABs levels exceeded the 97.5th percentile of

202 AAB levels of the analysed HCW sera and 27 samples that scored close to, but below this

203 cut-off were assessed by competition assay using unbiotinylated IFN-α2 or IFN-ω. The sera

- 204 of interest were diluted 1:100 with blocking buffer and incubated overnight at 4°C with
- 205 2.5mg/ml, 0.025mg/ml, and 0.00025mg/ml unbiotinylated IFN-α2 or IFN-ω. After incubation,
- 206 reverse ELISA was performed, as described above. IFN-AABs in a given serum scored
- 207 specific when preincubation with the highest concentration of IFN- α 2 or IFN- ω resulted in an
- at least four-fold reduction of LSC in comparison to analysis of the identical serum without
- 209 IFN- α 2 or IFN- ω pre-incubation.

210

211 Virus infection-based neutralization assays

Calu-3 cells were pre-incubated with 1% human serum in the presence or absence of 200-400 IU/ml IFN- α 2a (Roferon®-A, Roche) or 20-50 ng/ml IFN- ω (PeproTech). After 24 hours, IFN and serum were removed and cells were infected with SARS-CoV-2 at MOI 0.01. Virus inoculum was removed after one hour, cells were washed with PBS and 100 µl medium was

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

- added per well. 24 hours post-infection, cell culture supernatant was collected for viral RNA
- 217 quantification by RT-PCR and infectious titer determination by plaque assay.
- 218

219 Cytokine and chemokine measurements

- 220 Cytokines and chemokines from a subset of patients from cohort A were analyzed using
- 221 Quanterix' single molecule array technology or multiplex ECLIA.

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

223 RESULTS

224 We analyzed 430 serum samples collected within four independent observational clinical 225 studies on COVID-19 for IFN-AAB positivity (Table 1). Median age of patients in the CSC 226 was 61 years (IQR 52-71) and 72.2% (291/403) were male. Median Charlson Comorbidity 227 Index (CCI) was 3 (IQR 1-4). 27 patients with critical disease course (median max. WHO 228 score 7 (IQR 7-8)) who underwent TPE as compassionate use were selected retrospectively 229 from center D (TPEC). Median age of patients in the TPEC was 65 years (IQR 56-72), 74.1 230 % (20/27) were male and median CCI was 4 (IQR 3-5). All patients from the TPEC required 231 invasive mechanical ventilation (IMV), 77.8% (21/27) hemodialysis, one patient was treated 232 with extracorporeal membrane oxygenation (ECMO), and 13 out of 27 (48.2%) patients died 233 despite maximum care. 667 serum samples from a healthy cohort (HC) consisting of health-234 care workers (Table S1) were screened for the presence of neutralizing IFN-AABs to set the 235 cut-off for IFN-AAB positivity.

236

237 Prevalence of AABs against IFN- α 2 and IFN- ω in patients with COVID-19

238 We first aimed to establish a sensitive screening assay for type I IFN-AABs. To this end, we 239 first screened samples of our HC for prevalence of AABs against IFN-a and/or IFN-a by 240 ELISA. Samples were considered positive when the respective LSC value exceeded the 241 97.5th percentile of AAB levels of the analyzed sera from the HC (cut-off for IFN-a = 1980 242 LSC, IFN- ω = 1961 LSC). We then screened sera obtained at the peak of the disease from 243 patients of cohorts A-C (CSC) and cohort D (TPEC). The proportion of ELISA-positive 244 patients in the CSC was 5.0% (20/403) for IFN- AABs and 4.2% (17/403) for IFN- AABs. 245 It was significantly higher in cohort D (TPEC) (IFN-q AABs 18.5%, 5/27, p = 0.0035 and IFN-246 \oplus AABs 14.8%, 4/27, p = 0.0132), as expected (Fig. 1a, Fig. S1). Some sera displayed

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

values approaching or equaling those detected in sera from patients with APS-1, a genetic
disease involving the generation of high titer neutralizing type I IFN-AABs (Fig. 1a, (Meisel et
al. 2021)).
Nonspecific binding is a common phenomenon in immunoassays for the detection of
AABs, and high levels of inflammatory parameters such as CRP correlate with non-specific
binding of (auto-)antibodies (Güven et al. 2014). Therefore, we probed the specificity of all

253 samples exceeding the 97.5th percentile of the IFN-AAB ELISA and 27 samples that scored

right below the cut-off in a competition assay (Fig. 1b). Based on the assumption that sera scoring below the cut-off did not contain IFN-AABs, we established a prevalence of specific

256 IFN-□-AAB of 3.2% (13/403) and of specific IFN-0-AAB of 1.7% (7/403) in the CSC (Fig. 1a-

b). Cohort D (TPEC) showed 18.5% of sera specifically binding IFN-□ (5/27) and 14.8% for

258 IFN-ω (4/27) or both (14.8%, 4/27) (Fig. 1a-b). As expected, all tested samples scoring below

the 97.5th percentile in the ELISA scored negative in the specificity assay with the exception

260 of one patient (B044) who scored slightly below the cut-off in the IFN-ω-AAB assay.

Importantly, none of the tested sera from the HC displayed antibodies that specifically bound
IFN-□ or IFN-□.

263

264 IFN-AABs neutralize exogenous IFN in a virus infection-based assay

We next analyzed whether the presence of detectable and specifically IFN-binding AABs corresponded to a functional neutralization of IFN during infection. To this end, we applied a previously established assay of IFN-based inhibition of SARS-CoV-2 infection of the immortalized lung cell line Calu-3 (Meisel et al. 2021), which we consider the gold standard for analysis of IFN neutralization. We tested the extent to which sera neutralize the antiviral activity of type I IFNs, resulting in efficient infection despite presence of IFNs. We tested all ELISA-positive sera as well as 102 ELISA-negative sera as a reference. 13 (3.2 %) and 8

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

(2.0 %) of the 403 sera of the CSC specifically neutralized exogenous IFN-□ and IFN-□,
respectively, as judged by PCR-based quantification of SARS-CoV-2 genomic RNA in the
supernatant and plaque assays that quantify infectivity of virus progeny (Fig. 2a-b, Fig. S1).
In cohort D (TPEC), 5 (18.5%) and 3 (11.1%) of 27 sera neutralized IFN-□ and IFN-□
activity, respectively (Fig. 2a-b, Fig. S1).

277 Strikingly, among competition assay-positive samples, 18 (100%) of 18, and 9 (90%) 278 of 10 sera displayed IFN- and IFN---neutralizing activity, respectively, indicating that a 279 positive result in the competition assay associates with neutralization activity with a high 280 likelihood (Fig. 1c-d). Conversely, a negative result in the competition assay was predictive 281 of absence of neutralization ability. Specifically, among ELISA-positive, but competition 282 assay-negative sera, 0 (0%) of 23 and 0 (0%) of 29 sera were able to neutralize IFN-□ and 283 IFN-□, respectively. Among IFN-α AAB-ELISA-negative sera, we observed no IFN-284 neutralizing activity. Interestingly, among IFN- ω AAB-ELISA-negative sera, we identified two 285 samples that neutralized IFN- ω despite scoring negative in the IFN- ω -AAB ELISA (i.e., 286 having LSC counts below the 97.5th percentile cut-off) (Fig. 2b, d). The pronounced ability of 287 these exact two sera to neutralize IFN- α (Fig. 2a, c) was the reason why we included them in 288 the IFN- ω test, and suggests a potential cross-reactivity of IFN- α -AAB with IFN- ω .

Merging results from all three assays (Fig. 2c-d) revealed that an LSC value in the screening ELISA of >35.639 (IFN-□) and >12.603 (IFN-□) predicted specific binding in the competition assay and neutralization ability in the functional assay. Finally, the prevalence of ten individual antiphospholipid-ABs did not differ between patients with and without neutralizing IFN-AABs from cohort A (Fig. S2), suggesting that the presence of AABs is not generally increased in IFN-AAB-positive patients.

295

296 Clinical phenotype of COVID-19 patients displaying type-I IFN-AABs

We next aimed to characterize the clinical phenotype of IFN-neutralizing AAB-positive COVID-19 patients in the CSC at hospital admission, and to identify discriminatory markers that may serve as pre-selection criteria for their early identification and stratification.

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

300 Interestingly, there were no statistically significant differences regarding clinical baseline 301 characteristics, including demographic criteria and pre-existing comorbidities between 302 patients with and without IFN-neutralizing AABs in the CSC using univariate analyses (Table 303 1). Yet, of all patients with available symptom records (cohorts A and C), the proportion of 304 patients who reported fever and required supplemental oxygen therapy within 72 hours from 305 admission was higher in patients with neutralizing IFN-AABs than in those without (fever: 306 100%, 12/12 versus 62.6% (234/374), p=0.0079 and oxygen: 100% (12/12) versus 76.0% 307 (250/329), p=0.0528).

308 Furthermore, patients with IFN-AABs for which respective data were available 309 displayed higher median values of C-reactive protein (CRP), procalcitonin, lactate 310 dehydrogenase (LDH), ferritin, total leukocyte and neutrophil count, as well as neutrophil-to-311 lymphocyte ratio within the first three days of hospital admission compared to patients 312 without IFN-AABs (Fig. 3, Fig. S3). In addition, patients with neutralizing IFN-AABs showed 313 low levels of CD169/Siglec-1 expression on monocytes, a well-known type I IFN-response 314 marker (Fig. S4). Interestingly, there was a tendency towards a negative correlation between 315 CRP levels and CD169/Siglec-1 within 72 hours from hospital admission.

316

In IFN-AAB-positive patients, high quantities of neutralizing IFN-α2-AABs were
 present both soon post-symptom onset and at the peak of disease

Next, we evaluated the temporal dynamics of IFN-AAB levels in sera from COVID-19 patients soon after symptom onset as compared to the peak of the disease. Available samples obtained in cohort A, and in cohort D (TPEC) prior to TPE were analyzed (Fig. 4, Fig. S5). In all patient sera with detectable neutralizing IFN-AABs at the peak of the disease, early sera corresponding to ten (min. 4 - max. 20) days post-symptom onset (PSO) contained abundant and neutralizing (Fig. 4, Fig. S5) IFN-AABs, suggesting that IFN-AABs either existed prior to the infection or were generated very early PSO.

326

327

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

328 Cytokine and humoral responses to SARS-CoV-2 infection in IFN-AAB-positive 329 patients

330 We next aimed to identify potential quantitative and/or qualitative differences in cytokine 331 responses, viral load and seroconversion kinetics in IFN-AAB-positive as opposed to IFN-332 AAB-negative patients. We analyzed serum cytokine levels in a subset of critical patients 333 (WHO max. 6-8) from cohort A. Patients with neutralizing IFN-AABs demonstrated 334 significantly higher levels of IFN-y, and IFN-y-induced protein 10 (IP-10) one to two weeks 335 PSO while monocyte chemoattractant protein-1 (MCP-1) and TNF-α concentrations were 336 similar compared to sera from patients without neutralizing IFN-AABs (Fig. S6). However, levels equalized among the two groups at three to four weeks PSO. As expected, patients 337 338 with IFN-AABs had undetectable serum IFN
levels. Of note, by comparing upper-339 respiratory tract swabs and sera from patients with and without IFN-AABs from all infected 340 cohorts, we failed to identify detectable differences in viral load level or decay over time (Fig. 341 S7a) and we found no evidence for a difference in duration until seroconversion PSO (Fig. 342 S7b). In conclusion, some cytokine responses were aberrantly elevated in patients with IFN-343 AABs within the first two weeks PSO. However, they normalized at weeks three and four, 344 and viral RNA production and time to seroconversion remained indistinguishable from 345 patients without IFN-AABs.

346

347 Clinical Outcome of COVID-19 Patients with Neutralizing IFN-AABs

Neutralizing IFN-AAB-positive patients developed significantly higher max. WHO scores than patients without neutralizing IFN-AABs (median max. WHO score 8 (IQR 8-8) vs 6 (IQR 4-7), respectively; p<0.0001, Fig. 5a). All patients with neutralizing IFN-AABs in the CSC required IMV (13/13, 100%), compared to 44.5% (166/372) in patients without IFN-AABs (p<0.0001, Fig. 5b). Similarly, the proportion of neutralizing IFN-AAB-positive patients requiring haemodialysis and/or ECMO was markedly higher than in those without IFN-AABs (haemodialysis: 69.2%, 9/13 versus 26.6%, 98/369, p = 0.0008, ECMO: 46.2%, 6/13 versus

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

355	15.6%, 58/372, p = 0.0036, Table 1). Twelve out of thirteen neutralizing IFN-AAB-positive
356	patients (92.3%) died in hospital compared to 19.1% (71/372) of patients without IFN-AABs
357	(p<0.0001) in the CSC (Table 1). Median survival of patients with neutralizing IFN-AABs was
358	28 days (IQR 22-65 days). The probability of surviving to 150 days PSO is 81.3% (300/369)
359	for the patients from the non-neutralizing group, as opposed to 7.7% (1/13) for the patients
360	of the neutralizing IFN-AAB-positive group (Fig. 5c). Conclusively, IFN-AAB positivity was
361	associated with severe disease trajectories of COVID-19 and a worse clinical outcome in our
362	cohorts.

363

Inter-individual effect of therapeutic plasma exchange on IFN-AABs and SARS-CoV-2 antibodies.

366 Cohort D (TPEC) allowed us to compare trajectories of IFN-AAB-positive patients 367 undergoing TPE to those not undergoing TPE. Criteria for initiation of TPE were: presence of 368 ARDS requiring IMV and/or vasopressor-dependent circulatory shock, clinical and laboratory features of a COVID-19 associated immunopathology with elevated D-dimers and ferritin 369 370 levels, persistent and refractory fever \geq 38.5°C without conclusive pathogenic evidence and 371 despite anti-infectious treatment. TPE was first initiated without prior screening for IFN-AABs 372 within a median of six days (IQR 1-10) after hospital admission and the median number of 373 TPE sessions per patient was 3 (IQR 2-5). TPE was performed using a continuous-flow 374 centrifugation blood cell separator. Plasma with enclosed cytokines and immunoglobulins 375 are separated from blood cells by gravity due to different densities of the respective blood 376 components (Nusshag et al. 2021).

Focusing on patients of the WHO group 6-8, survival of IFN-AAB-negative patients in the CSC cohorts and TPEC was similar (p = 0.34). The proportion of neutralizing IFN-AABpositive patients from the TPEC that survived in hospital was higher than of those patients from the CSC who did not undergo TPE (60%, 3/5 patients from the TPEC survived versus 7.7%, 1/13 patients from the CSC, p=0.0412) (Fig. 6a).

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

382 Longitudinal analysis of sera revealed that three (D011, D017, D018) out of five 383 patients responded to TPE with decreasing IFN-AAB levels below the cut-off and to a level 384 that coincided with absence of neutralizing activity. In addition, a sustained reduction of IFN-385 AAB quantities was achieved only by repetitive TPE (Fig. 5b, Fig. S8). In contrast to IFN-386 AABs, quantities of SARS-CoV-2 Spike IgG and IgA were less, if at all, affected by TPE 387 (note the logarithmic scale for IFN-AABs versus the linear scale for SARS-CoV-2-lgG/lgA). 388 Overall, our findings in a limited number of patients suggest that TPE could positively affect 389 the survival of critically ill IFN-AAB-positive patients. This needs to be corroborated in future, 390 adequately powered clinical investigations. Potentially, a sustained and significant reduction 391 of peripheral IFN-AAB levels must be achieved to prevent death.

392

393 Diagnostic algorithm for rapid identification of neutralizing IFN-AAB-positive patients

394 Given that IFN-AABs are risk factors for a worse clinical outcome in hospitalized patients 395 with COVID-19, future rapid identification of IFN-AAB-positive patients after hospital 396 admission seems key for the potential implementation and success of specific interventions 397 such as TPE. In the CSC cohort, the patient number needed to screen (NNS) without 398 preselection in order to identify one patient with neutralizing IFN-AAB was 31.0 (403/13). We 399 hypothesized that applying clinical pre-selection criteria which strongly co-present with the 400 neutralizing IFN-AAB positivity diminishes the NNS. Using univariate analyses, we 401 established that temperature (>38.5 °C or self-reported) before or upon hospital admission 402 and the need for supplemental oxygen within the first 72 hours after admission correlated 403 best with presence of IFN-AAB positivity in the screening assay in all hospitalized COVID-19 404 patients (fever: p=0.0079; supplemental oxygen p=0.0528). Using fever and need for 405 supplemental oxygen, the NNS was reduced to 15.6 (172/11). Selection of patients 406 exceeding the cut-off for ELISA positivity (in our cohort 97.5th percentile of the HC) for 407 further testing by competition assay would adjust the NNS in the competition assay to 1.4 408 (15/11). Therefore, in order to increase sensitivity, we propose to consider the need for

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault et al.

supplemental oxygen within 72 hours after admission and fever as pre-selection criteria forpatients that undergo ELISA screening (Fig. 7).

Sera from all patients exceeding the LSC value of 35,639 (13/13) in the screening ELISA assay demonstrated neutralizing activity against IFN- α (Fig. 2c). We therefore propose to conduct the IFN neutralization assay only in case of an LSC value lower than 35,639, whereas patients with sera exceeding this value can be considered positive for neutralizing IFN-AABs without further testing (Fig. 7).

416

417 DISCUSSION

418 IFN-AABs strongly associate with adverse clinical outcome of SARS-CoV-2 infection 419 (Bastard et al. 2020; Koning et al. 2021; Troya et al. 2021; Goncalves et al. 2021; Bastard et 420 al. 2021; Lemarquis et al. 2021; de Prost et al. 2021). Unfortunately, the inability to identify 421 IFN-AAB-positive COVID-19 patients early enough before deterioration delays their access 422 to specific, yet untested therapies that may require implementation directly upon hospital 423 admission. In several studies, detection and quantification of IFN-AABs in sera from COVID-424 19 patients relies on ELISA and multiplex particle-based assay. While these assays are 425 amenable to high-throughput and are highly sensitive, they result in a small proportion of 426 false-positive results (Güven et al. 2014; Sahud et al. 2012), highlighting the ongoing need to 427 reanalyze positive-tested patient material in functional assays demonstrating the 428 neutralization activity. However, such assays are sophisticated and time-consuming. They 429 include luciferase-based interferon-stimulated response element (ISRE) promoter reporter 430 assays (Troya et al. 2021; Goncalves et al. 2021), flow cytometry-based analyses of STAT 431 phosphorylation (Bastard et al. 2020; Goncalves et al. 2021; Meisel et al. 2021), and virus 432 infection-based assays (de Prost et al. 2021; Meisel et al. 2021). The latter allows probing 433 the activity of the IFN-AABs in the context of infection-inhibitory concentrations of IFN- α and 434 IFN-w. Here, we applied and cross-validated previously established assays comprising an 435 ELISA for sensitive identification, a specificity-validating competition assay, and a functional 436 neutralization assay (Meisel et al. 2021) using a large collection of serum samples obtained

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

437 from three cross-sectional cohorts. Equally important, we identified clinical parameters that 438 co-present with IFN-AAB positivity at hospital admission. Combination of clinical parameters 439 and targeted diagnostic testing results in an algorithm for early, sensitive, specific 440 identification of IFN-AAB-positive patients which can be easily introduced into clinical routine 441 diagnostics.

Surprisingly, sera from two patients were found to neutralize exogenous IFN- ω despite negative ELISA results. Presence of neutralization activity in the absence of detectable IFN-AABs has been reported (Bastard et al. 2021). Explanations for this phenomenon could include technical aspects of the detection method, including the possibility that IFN-AABs may be concealed by the binding of the cytokine to the plate or biotinylation of the cytokine (Meyer et al. 2016).

448 Here, we calibrated our ELISA cut-off based on the 97.5th percentile in a cohort of 449 uninfected individuals. Although this strategy may be inexact, the absence of prevalence 450 IFN-AABs in a cohort of younger and predominantly female healthcare workers supports an 451 age-dependent increase of IFN-AAB prevalence in uninfected individuals (Bastard et al. 452 2021). Furthermore, the prevalence of 3.2% (13/403) of patients with neutralizing AABs 453 against IFN- α and/or IFN- ω in our cross-sectional patient cohort (median max. WHO score 454 6) and 18.5% (5/27) in critically affected patients (median max. WHO-Score 7) is in line with 455 reported prevalences of 6-17% in severely (Bastard et al. 2020; Koning et al. 2021; Troya et 456 al. 2021; van der Wijst et al. 2021) and 11-19% in critically ill (Bastard et al. 2020; van der 457 Wijst et al. 2021; Goncalves et al. 2021) individuals with COVID-19. Moreover, IFN-AAB 458 positivity is associated with a worse clinical outcome and a decreased survival probability of 459 hospitalized patients in our cohorts, confirming previous reports (Bastard et al. 2020; Koning 460 et al. 2021; Troya et al. 2021; Goncalves et al. 2021; Bastard et al. 2021; Lemarquis et al. 461 2021; de Prost et al. 2021). Interestingly, a single study to date (Abers et al. 2021) 462 suggested that survival was not adversely affected by the presence of type-I IFN-AABs, 463 while confirming the widely accepted association with an increased risk of admission to the 464 intensive care unit.

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

465 We failed to identify a clear association of IFN-AABs with previously described 466 demographic parameters in our cross-sectional cohort, including male sex or advanced age 467 (Bastard et al. 2020, 2021), probably due to the relatively limited sample size of our cohorts. 468 However, the presence of neutralizing IFN-AABs was associated with fever and need for 469 supplementary oxygen within 72 hours post hospital admission, as well as with elevated 470 soluble and cellular markers of acute-phase reaction including elevated levels of CRP, 471 procalcitonin, LDH and ferritin and elevated total neutrophil and leukocyte counts within the 472 first three days of admission in our CSC. Higher CRP values constitute a biomarker for a 473 severe disease course, are included in a widely-used clinical risk score for mortality of 474 COVID-19 (Knight et al. 2020), and associate with neutralizing IFN-AABs along with lower 475 lymphocyte counts in severely affected patients (Troya et al. 2021). As hospital admission 476 and thus clinical deterioration occurred at a median of five days PSO in the CSC, we 477 propose fever and need for supplemental oxygen therapy up to 72 hours post hospital 478 admission as suitable and simple clinical criteria to identify patients at risk for a severe 479 disease course.

480 Our ability to detect IFN-AABs as early as four days PSO in sera from most patients 481 that present with IFN-AABs at the peak of their disease suggest that they were present prior 482 to the infection, or alternatively, but less likely, were induced very early post infection. Our 483 data are in agreement with recently demonstrated presence of IFN-AABs at the day of 484 hospital admission (de Prost et al. 2021) and in 4% of uninfected individuals >70 years old 485 (Bastard et al. 2021), underlining the idea that they can serve as biomarkers for 486 predisposition for a severe course of SARS-CoV-2 infection. Future studies are required to 487 elucidate the biological mechanisms that lead to elicitation of IFN-AABs in an age-dependent 488 manner.

489 Currently discussed therapeutic options tailored to IFN-AAB-positive COVID-19 490 patients comprise mainly TPE and IFN-β administration. TPE in the context of COVID-19 491 has been analyzed in individual case reports and case-control studies, including IFN-AAB-492 positive and negative patients (Lemarguis et al. 2021; Nusshag et al. 2021; de Prost et al.

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

493 2021; Fernandez et al. 2020) and might efficiently remove soluble circulating Fc gamma 494 receptor-activating immune complexes (Ankerhold et al. 2021). TPE effectively decreased 495 circulating IFN-AAB, but not SARS-CoV-2 antibody concentrations in four IFN-AAB-positive, 496 severely ill patients (de Prost et al. 2021) and in a child with APS-1 suffering from severe 497 COVID-19 (Lemarquis et al. 2021). In our study, TPE reduced circulating IFN-AABs with 498 patient-specific efficiency and appeared to increase the chances of in-hospital survival, 499 underlining the rationale to initiate large-scale, adequately powered clinical trials in order to 500 corroborate the potential benefit of TPE in a general cohort of adult, critically ill COVID-19 501 patients. Interestingly, SARS-CoV-2-IgG and IgA quantities were less affected by TPE for 502 unknown reasons, which may include their rapid replenishment by highly abundant 503 plasmablasts or an extravascular-to-intravascular rebound since immunoglobulins have a 504 substantial extravascular distribution.

Given the reported absence of detectable IFN-β-AABs, IFN-β administration may substitute neutralized IFN- α and - ω . While IFN-β therapy failed to result in a detectable clinical benefit in the SOLIDARITY trial (WHO Solidarity Trial Consortium et al. 2021), specifically IFN-AAB-positive patients may benefit from IFN-β therapy, a patient group that might have been under-represented in this study. Furthermore, the benefit of IFN-β administered by different routes should be systematically explored in this patient group.

511

512

513 CONCLUSIONS

514 Generation of comprehensive data on the clinical benefit of TPE and IFN-β therapy 515 are hampered by the difficulty of identifying IFN-AAB-positive patients for enrollment in large 516 clinical studies. Our diagnostic algorithm for their identification may support clinicians to 517 promptly identify patients carrying this additional risk factor for progression to severe disease 518 upon hospital admission. It is based on clinical preselection of patients presenting with fever 519 and need for supplemental oxygen therapy within 72 hours after admission to be further 520 screened by an ELISA-based assay for circulating IFN-AABs and an easily implementable

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

521 ELISA-based validation assay which may be skipped in case of high positivity in the 522 screening assay (Fig. 7). Screening criteria should be validated in the future in a large 523 prospective observational cohort. Ideally, methodological complex gold-standard assays can 524 be substituted by high-throughput diagnostic tests and stratification by clinical parameters, 525 facilitating clinical implementation. Our algorithm may allow identifying at-risk patients upon 526 presentation in the emergency room to be directly allocated to TPE and/or IFN-β therapy 527 within larger clinical trials, which are urgently needed to determine clinical effectiveness of 528 these targeted therapies.

529

530 Acknowledgements

531 We thank Mahtab Maleki for support with IFN-AAB ELISAs and competition assays. We 532 thank Patricia Tscheak, Marie Luisa Schmidt, and Tatjana Schwarz for support with sample logistics and SARS-CoV-2 antibody testing. V.M.C is a participant of the Charité Clinician 533 534 Scientist program funded by Charité – Universitätsmedizin Berlin and the Berlin Institute of 535 Health. We thank Karin Reiter for the anti-phospholipid antibody measurements. We thank 536 the patients for their ongoing trust and collaboration. We thank the involved biobanks 537 (ZeBanC Berlin, FREEZE-Biobank Freiburg) for their support. DD and AL are members of 538 SFB1425, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research 539 Foundation) – Project #422681845. NS is partly funded by the Deutsche 540 Forschungsgemeinschaft (DFG, Research Grant No. SCHA1838/4-2).

541

542 Pa-COVID study Group (Consortium representative: Florian Kurth)

Set up study platform: Stefan Hippenstiel⁴, Martin Witzenrath⁴, Elisa T. Helbig⁴, Lena J.
Lippert⁴, Pinkus Tober-Lau⁴, David Hillus⁴, Sarah Steinbrecher⁴, Sascha S. Haenel⁴,
Alexandra Horn⁴, Willi M⁴. Koch, Nadine Olk⁴, Rosa C. Schuhmacher⁴, Katrin K. Stoyanova⁴,
Lisa Ruby⁴, Claudia Zensen⁴, Mirja Mittermaier⁴, Fridolin Steinbeis⁴, Tilman Lingscheid⁴,
Bettina Temmesfeld-Wollbrück⁴, Thomas Zoller⁴, Holger Müller-Redetzky⁴, Alexander Uhrig⁴,
Daniel Grund⁴, Christoph Ruwwe-Glösenkamp⁴, Miriam S. Stegemann⁴, Katrin M. Heim⁴,

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

Bastian Opitz⁴, Kai-Uwe Eckardt²⁶, Martin Möckel²⁷, Felix Balzer²⁸, Claudia Spies²⁸, Steffen
Weber-Carstens²⁸, Frank Tacke²⁹, Chantip Dang-Heine², Michael Hummel³⁰, Georg
Schwanitz³¹, Uwe D. Behrens³¹, Maria Rönnefarth², Sein Schmidt², Alexander Krannich²,
Saskia Zvorc², Jenny Kollek² and Christof von Kalle².

553

Inclusion of patients and clinical data curation: Linda Jürgens⁴, Malte Kleinschmidt⁴, Sophy 554 Denker³², Moritz Pfeiffer⁴, Belén Millet Pascual-Leone⁴, Luisa Mrziglod⁴, Felix Machleidt⁴, 555 Sebastian Albus⁴, Felix Bremer⁴, Tim Andermann⁴, Carmen Garcia⁴, Philipp Knape⁴, Philipp 556 M. Krause⁴, Liron Lechtenberg⁴, Yaosi Li⁴, Panagiotis Pergantis⁴, Till Jacobi⁴, Teresa 557 Ritter²⁶, Berna Yedikat⁴, Lennart Pfannkuch⁴, Ute Kellermann⁴, Susanne Fieberg⁴, Laure 558 559 Bosquillon de Jarcy¹, Anne Wetzel⁴, Markus C. Brack⁴, Moritz Müller-Plathe⁴, Jan M. Kruse²⁶, Daniel Zickler²⁶, Andreas Edel²⁸, Britta Stier²⁶, Roland Körner²⁶, Nils B. Müller²⁶, 560 Philipp Enghard²⁶, Lucie Kretzler², Lil A. Meyer-Arndt³³, Linna Li², and Isabelle Wirsching² 561

562

Biobanking and -sampling: Denise Treue³⁰, Dana Briesemeister³⁰, Jenny Schlesinger³⁰,
Birgit Sawitzki²⁵, Lara Bardtke⁴, Kai Pohl⁴, Philipp Georg⁴, Daniel Wendisch⁴, Anna L. Hiller⁴,
Sophie Brumhard⁴, Marie Luisa Schmidt¹, Leonie Meiners¹, and Patricia Tscheak¹

566

567 Study Group-Specific Affiliations:

²⁶Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and
 Humboldt-Universität zu Berlin, Institute of Nephrology and Internal Intensive Care Medicine,
 Berlin, Germany

²⁷Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and
 Humboldt-Universität zu Berlin, Division of Emergency Medicine and Department of
 Cardiology, Berlin, Germany

²⁸Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and
 Humboldt-Universität zu Berlin, Department of Anesthesiology and Intensive Care Medicine,
 Berlin, Germany

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

577	²⁹ Charité – Universitä	itsm	edizin E	Berlin, corpor	ate	member of	f Freie	e Universität Ber	lin and
578	Humboldt-Universität	zu	Berlin,	Department	of	Hepatology	and	Gastroenterology,	Berlin,
579	Germany								

- 580 ³⁰Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and
- 581 Humboldt-Universität zu Berlin, Central Biobank Charité (ZeBanC), Institute of Pathology,
- 582 Berlin, Germany
- ³¹Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and
 Humboldt-Universität zu Berlin, Clinical Study Center, Berlin, Germany
- 585 ³²Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and
- 586 Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumor
- 587 Immunology, Berlin, Germany
- 588 ³³Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and
- 589 Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

591

592

593 Author contributions

- 594 Conceptualization: Florian Kurth; Horst von Bernuth; Christian Meisel; Christine Goffinet
- 595 *Methodology*: Bengisu Akbil; Tim Meyer; Olga Staudacher
- 596 Formal analysis and investigation: Bengisu Akbil; Tim Meyer; Paula Stubbemann; Charlotte

597 Thibeault; Olga Staudacher; Jenny Jansen; Barbara Mühlebach; Jan-Moritz Doehn;

598 Christoph Tabeling; Christian Nusshag, Cédric Hirzel; David Sökler Sanchez; Daniel

599 Duerschmied, Achim Lother; Nils Schallner; Jan Nikolaus Lieberum; Dietrich August;

600 Siegbert Rieg; Valeria Falcone; Uwe Kölsch; Nadine Unterwalder; Thibaud Spinetti; Joerg

- 601 Schefold; Thomas Dörner; Victor M. Corman; Uta Merle
- 602 *Writing original draft preparation*: Paula Stubbemann; Charlotte Thibeault; Christine 603 Gofffinet
- 604 Writing review and editing: Bengisu Akbil; Tim Meyer; Paula Stubbemann; Charlotte

605 Thibeault; Olga Staudacher; Daniela Niemeyer; Barbara Mühlemann; Christian Nusshag;

606 Daniel Duerschmied, Achim Lother; Terry C. Jones; Klaus Warnatz; Thibaud Spinetti; Joerg

- 607 C. Schefold; Leif Sander; Victor M. Corman; Uta Merle; Florian Kurth; Horst von Bernuth;
- 608 Christian Meisel; Christine Goffinet

609 Funding acquisition: Joerg Schefold; Klaus Warnatz; Uta Merle; Florian Kurth; Horst von

610 Bernuth; Christian Meisel; Christine Goffinet

611 Resources: Daniela Niemeyer, Alexandra Nieters; Christian Drosten; Leif Sander; Florian

- 612 Kurth; Horst von Bernuth; Christian Meisel; Christine Goffinet
- 613 Supervision: Hartmut Hengel; Ralf-Harto Hübner; Norbert Suttorp; Klaus Warnatz; Victor M.
- 614 Corman; Florian Kurth; Horst von Bernuth; Christian Meisel; Christine Goffinet

615

616 Funding

- 617 This work was supported by the Innovationsfond of Labor Berlin (to H.V.B, C.M., and C.G.);
- 618 by funding from the Deutsche Forschungsgemeinschaft (DFG) Collaborative Research

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

619 Centre CRC900 "Microbial Persistence and its Control," project number 158989968, project 620 C8 (awarded to C.G.); by funding from the Berlin Institute of Health (BIH) (to C.G.). T.C.J. is 621 in part funded through NIAID-NIH CEIRS contract HHSN272201400008C. Parts of the work 622 were funded by the European Union's Horizon 2020 research and innovation program 623 through project RECOVER (GA101003589) to C.D.; the German Ministry of Research 624 through the projects VARIPath (01KI2021) to V.M.C., and NaFoUniMedCovid19 - COVIM, 625 FKZ: 01KX2021 to C.D., V.M.C., L.E.S., F.K. and H.H. The Pa-COVID-19 Study is funded by 626 BIH and the German Ministry of Research NaFoUniMedCovid19 NUM-NAPKON FKZ: 627 01KX2021. The COV-IMMUN study is supported by the Berlin University Alliance and the 628 BIH Clinical Study Center (BIH-CSC). KW has received funding by the Deutsche 629 Forschungsgemeinschaft (DFG, Research Grant No. WA 1597/6-1 and WA 1597/7-1).

630

631 Disclosure of Conflicts of interest

632 V.M.C is named together with Euroimmun GmbH on a patent application filed recently 633 regarding the diagnostic of SARS-CoV-2 by antibody testing. Technische Universität Berlin, 634 Freie Universität Berlin and Charité - Universitätsmedizin have filed a patent application for 635 siRNAs inhibiting SARS-CoV-2 replication with D.N. as co-author. J.C.S, T.S (full 636 departmental disclosure): the department of Intensive Care Medicine has/had research 637 and/or development/consulting contracts with (full disclosure) Orion Corporation, Abbott 638 Nutrition International, B. Braun Medical AG, CSEM SA, Edwards Lifesciences Services 639 GmbH/SA, Kenta Biotech Ltd, Maquet Critical Care AB, Omnicare Clinical Research AG, 640 Phagenesis Ltd, Cytel, and Nestlé. No personal financial gains resulted from respective 641 development/consulting contracts and/or educational grants.

642

643 Research involving human participants

All studies were conducted according to the Declaration of Helsinki and Good ClinicalPractice principles (ICH 1996).

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

The Pa-COVID-19 study was approved by the ethics committee of Charité –
Universitätsmedizin Berlin (EA2/066/20) and is registered in the German and WHO
international clinical trials registry (DRKS00021688).

649 The Covimmun-study was approved by the ethics committee of Charité –
650 Universitätsmedizin Berlin (EA1/068/20).

The study "Evaluation der humoralen und zellulären Immunantwort und der thromboembolischen Komplikationen bei Infektion mit dem neuartigen Coronavirus (nCoV19)" was approved by the Kantonale Ethikkommission KEK, Bern, Switzerland, Nr. 2020-00877 and is registered under the name "Characterizing the Immune Response and Neuronal Damage in COVID-19" at <u>http://clinicaltrials.gov</u> (NCT04510012).

The three studies (COVID-19 Register Freiburg; FREEZE-Covid19 cohort and Biomarker COVID-19) were approved by the ethics committee of the University of Freiburg (EK-FR 153/20; FREEZE-Biobank EK-FR 383/19; EK-FR 225/20) and are registered in the German and WHO international clinical trials registry (DRKS00021522 for Biomarker COVID-19).

660 The Covid-Immun study was approved by the local Ethics Committee of the Medical Faculty 661 of Heidelberg (S148/2020) and is registered in the German clinical trials registry 662 (DRKS00021810).

663

664 Informed consent

665 Informed consent was obtained from all individual participants included in the studies.

666

667 Availability of data and material

668 The datasets and materials generated during and/or analyzed during the current study are 669 available from the corresponding authors on reasonable request.

670

671 Code availability

Not applicable. No data were coded in this study.

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

674

675

676 Legends

677

678 Figure 1. Prevalence of AABs against IFN- α 2 and IFN- ω in patients with COVID-19.

679 (a) ECLIA-based assay for detection of IgG AABs against IFN- α 2 and IFN- ω in sera from 680 hospitalized patients with COVID-19 from four different university hospital cohorts (Center A, 681 n=266; Center B, n=50; Center C, n=87; Center D, n=27), in patients with APS-1 (n=6), and 682 healthy health care workers (HC) without documented SARS-CoV-2 infection (n=667). 683 Dotted lines indicate the 97.5th percentile of the ECLIA assay LSC in sera from the HC 684 cohort. Dots indicate samples containing AABs scoring specific (red) or unspecific (blue) for 685 IFN- α 2 and IFN- ω binding in the competition assay (see b), respectively. The prevalence of 686 sera with specifically binding type I IFN-AABs in each cohort is given in percent.

687 (b) Specificity of the ECLIA assay signal for IFN- α 2- and IFN- ω -AABs was tested in an 688 competition assay by preincubation of sera with increasing concentrations of unlabeled IFN-689 $\alpha 2$ and IFN- ω protein (0 - 2.5 μ g/ml) before analysis. Samples showing a decrease in assay 690 signal by at least 75% in the presence of the highest competitor concentration were defined 691 as specific for type I IFN antibody reactivity and are indicated with red lines (IFN- $\alpha 2$ n=18, 692 IFN- ω n=11). Samples showing no decrease in the presence of excess unlabeled type I IFN 693 protein were regarded as unspecific for type I IFN antibody reactivity and are indicated with 694 blue lines (IFN- α 2 n=62, IFN- ω n=39).

695

696 Figure 2. IFN-AABs neutralize exogenous IFN in a virus infection-based assay.

(a-b) Selected sera were analyzed for IFN neutralization activity in a SARS-CoV-2 infectionbased assay. The ability of individual sera to neutralize exogenous IFN- α 2 (a) and IFN- ω (b) is shown by the rescue of susceptibility to infection as judged by quantification of viral RNA (x-axis) and infectivity (y-axis) in the supernatant. The infection condition in the absence of serum and IFN is set to 1.

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

(c-d) The LSC value for individual sera, grouped into non-neutralizing and neutralizing sera. Dots indicate sera containing AABs scoring specific (red) or unspecific (blue) for IFN- α 2 and IFN- ω binding in the competition assay (see b), respectively. Black dots indicate samples that scored below the threshold of the ELISA. Black dotted lines indicate the 97.5th percentile of the ECLIA assay LSC in sera from the healthy health care workers (HC) cohort (see Fig. 1). Neutralization ability of IFN- α and IFN- ω can be predicted at 100% for sera displaying LSCs above the respective red dotted lines (IFN- α : 35,639; IFN- ω : 12,603).

709

710 Figure 3: Clinical phenotype of COVID-19 patients displaying type-I IFN-AABs.

711 Values of C-reactive protein (CRP), procalcitonin, ferritin, lactate dehydrogenase (LDH),

absolute leukocyte and neutrophil count and neutrophil-to-lymphocyte ratio (NLR) of patients

with (N=5-6) and without neutralizing IFN-AABs (N=200-265) from the cross-sectional cohort

714 (CSC, all WHO scores). For each patient, the first available parameter within 72 hours of

hospital admission is shown. Statistical testing was performed with Mann-Whitney *U* test.

716

Figure 4. In IFN-AAB-positive patients, high quantities of neutralizing IFN-α2-AABs were present both soon PSO and at the peak of disease.

(a) Time course of antibody quantities in patient sera that scored IFN-AAB positive at the
peak of disease (N=8). The dotted line indicates the 97.5th percentile of the ECLIA assay
LSC in sera from the HC cohort (see Fig. 1).

(b-c) The ability of the sera to neutralize exogenous IFN-α2 is shown by the rescue of
susceptibility to infection as judged by quantification of viral RNA (b) and infectivity (c) in the
supernatant. The infection condition in the absence of serum and IFN is set to 1.

725

726 Figure 5: Clinical outcome of COVID-19 patients with neutralizing IFN-AABs.

727 (a) Median max. WHO score in hospital. Statistical testing was performed using the Mann-728 Whitney *U* test.

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault et al.

729 (b) Proportion of patients requiring invasive mechanical ventilation (IMV) after hospital

admission. Statistical testing was performed using the Chi-Square test.

731 (c) Probability of survival of patients with and without neutralizing IFN-AABs from the cross-

r32 sectional cohort (CSC) from symptom onset until discharge (up to 150 days), death or

733 transferral (p<0.0001). Statistical testing was performed using a log-rank test.

Neutralizing (N=13), non-neutralizing (N=372).

735

Figure 6. Inter-individual effect of therapeutic plasma exchange on IFN-AABs and
 SARS-CoV-2 antibodies.

(a) Probability of survival of neutralizing IFN-AAB-positive and -negative patients with critical
COVID-19 (max. WHO score 6-8) with and without plasma exchange (CSC and TPEC) from
symptom onset until discharge, death or transferral (p=0.04, neutralizing CSC versus
neutralizing TPEC). Statistical testing was performed using a log-rank test. Neutralizing CSC
(N=13), non-neutralizing CSC (N=184), neutralizing TEPC (N=5) and non-neutralizing TPEC
(N=22).

(**b**) Antibody profile in serum from individual COVID-19 patients of the TPEC subjected to plasma exchange. The quantity of IFN- α 2- and IFN- ω -AABs, SARS-CoV-2-IgG and -IgA, and the IFN- α 2 and IFN- ω neutralization status are given for various time points. The patient identifier is given in red. Viral load profiles were only available for patients D011 and D018 and are shown in Supplementary Figure 7.

749

750 Figure 7. Diagnostic algorithm for rapid identification of neutralizing IFN-AAB-positive

751 patients.

The number needed to screen (NNS) is based on results from the cross-sectional cohort (CSC). ELISA for IFN-AAB detection was considered to be positive if it exceeded the 97.5th percentile of the healthy control cohort. (1) NNS of all hospitalized Covid-19 patients without preselection was 31.0 (403 patients in total, 13 patients with neutralizing IFN-AABs). (2) Prescreening of patients using the clinical criteria of fever at admission and need for

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

757	supplemental oxygen within the first 72 hours after hospitalization diminished the NNS in the
758	IFN-AAB ELISA (3) by half, to 15.6 (172/11). For patients identified as positive in the
759	screening ELISA, the NNS in the competition assay to confirm the presence of IFN-specific
760	AABs is reduced to 1.4 (15/11) (4). For patients with high-titer IFN-AABs (light signal count >
761	35.639), the competition assay can be omitted. For patients highly positive in the IFN-AAB
762	ELISA and those with specific results in the competition assay, we propose to consider
763	therapeutic plasma exchange within clinical studies (5).
764	

7	65
1	00

		Individua	Il cohorts	CSC, Center A-C					
	Center A, Berlin cohort	Center B, Bern cohort	Center C, Freiburg cohort	Center D, Heidelberg cohort (TPEC)	Center A-C	IFN-AB Neutralizing	IFN-AB Non- neutralizing	p-value	
Number of patients	266	50	87	27	403	13	390	/	
IFN-AAB Neutralizing IFN-alpha Neutralizing IFN-omega	2.6 (7/266) 2.6 (7/266) 1.1 (3/266)	6.0 (3/50) 6.0 (3/50) 6.0 (3/50)	3.5 (3/87) 3.5 (3/87) 2.3 (2/87)	18.5 (5/27) 3.2 (13/403) 100 (13 18.5 (5/27) 3.2 (13/403) 100 (13 11.1 (3/27) 2.0 (8/403) 61.5 (8/		100 (13/13) 100 (13/13) 61.5 (8/13)	/	/	
Age (Median, IQR, available n)	61 (50-71), 266	67.3 (56.8-74.5), 50	59 (53-67), 87	65 (56-72), 27	.6-72), 27 61 (52-71), 403 69.4 (52.5-75.6), 13		61.0 (52-70.2), 390	0.19	
Sex Female Male	27.8 (74/266) 72.2 (193/266)	18.0 (9/50) 82.0 (41/50)	33.3 (29/87) 66.7 (58/87)	25.9 (7/27) 27.8 (112/403) 74.1 (20/27) 72.2 (291/403)		15.4 (2/13) 84.6 (11/13)	28.2 (110/390) 71.8 (280/390)	Male: 0.31	
BMI (kg/m ² , Median, IQR, available n)	28.4 (24,9-32,5), 245	27 (26-31), 47	27.7 (25.2-32.2), 56	31.5 (25.8-40.1), 27	5.8-40.1), 28 (25-32.3), 348 27.4 (25.5-29.5), 10		28 (24.9-32.4), 338	0.73	
Comorbidities CCI (Median, IQR, available n) Chronic heart disease (%) Chronic pulmonary disease (%) Diabetes (%) Obesity (%) Autoimmune disease (%)	2 (1-3.75), 265 58.9 (155/263) 18.5 (47/254) 26.7 (70/262) 39.2 (96/245) 2.8 (7/251)	4 (2-6.5), 33 30.3 (10/33) 27.3 (9/33) 42.4 (14/33) 31.9 (15/47) 2.0 (1/50)	3 (2-5), 83 23.0 (20/87) 10.4 (9/87) 26.4 (23/87) 28.6 (16/56) 5.7 (5/87)	4 (3-5), 27 77.8 (21/27) 3.7 (1/27) 44.4 (12/27) 55.6 (15/27) 3.7 (1/27)	3 (1-4), 380 48.3 (185/383) 17.4 (65/374) 28.0 (107/382) 36.5 (127/348) 3.4 (13/388)	3 (1.5-4), 13 46.2 (6/13) 23.1 (3/13) 23.1 (3/13) 20.0 (2/10) 0 (0/13)	3 (1-4), 367 48.4 (179/370) 17.2 (62/361) 28.2 (104/369) 37.0 (125/338) 3.5 (13/375)	0.54 0.69 0.58 0.54 0.27 0.72	
Symptoms: Fever	57.0 (151/265)	80.0 (40/50)	77.5 (55/71)	85.2 (23/27)	63.7 (246/386)	100 (12/12)	62.6 (234/374)	0.0079	
Days between symptom onset and admission (Median, IQR, available n)	6 (2-9), 233	4 (2-8), 50	6 (3-9), 66	6 (3-8), 27	5 (2-9), 349	4 (3-8), 11	5 (2-9), 338	0.81	
Need for supplementary oxygen within first 72 h after admission	78.4 (189/241)	74.0 (37/50)	72 (36/50)	100 (12/12)	76,8 (262/341)	100 (12/12)	76.0 (250/329)	0.0528	

IMV	46.2 (117/253)	60,0 (30/50)	39,0 (32/82)	100 (27/27)	46,4 (179/385)	100 (13/13)	44.5 (166/372)	0.0001
Days between symptom onset and intubation (Median, IQR, available n)	8 (4-10), 117	7 (3,75-10), 30	8 (3-11), 31	10 (7-15), 27	7 (4-10), 178	6 (5-11,5), 13	8 (4-10), 165	0.91
Days between hospital admission and intubation (Median, IQR, available n)	2 (0-4), 117	1,5 (0-3,25), 30	2 (1-7), 31	4 (0-6), 27	2 (0-4), 178	1 (0.5-4.5), 13	2 (0-4), 165	0.92
Length of ventilation in days (Median, IQR, available n)	32,5 (18,25-56,5), 116	10,5 (5-18,5), 30	16 (6-21), 23	24 (14-37), 27	23 (11-45), 169	20 (10.75-29.25), 12	24 (11-47,5), 157	0.40
Length of hospital stay in days (Median, IQR, available n)	20 (10-44), 262	13,5 (5-23,25), 50	16 (7-33), 85	41 (24-63), 27	19 (9-38), 397	25 (16-47), 13	17 (9-37,8), 384	0.045
Medication/treatment Dexamethasone Remdesivir	46.9 (123/262) 9,2 (16/174)	48.0 (24/50) 0 (0/50)	21.0 (17/87) 12.6 (11/87)	74,1 (20/27) 29.6 (8/27)	41.7 (164/393) 8.7 (27/311)	46.2 (6/13) 0 (0/13)	41.6 (158/380) 9.0 (27/300)	0.74 0.52
Renal replacement therapy	29.3 (74/253)	26.0 (13/50)	25.3 (20/79)	77.8 (21/27)	28.0 (107/382)	69.2 (9/13)	26.6 (98/369)	0.0008
ЕСМО	17.4 (44/253)	0 (0/50)	24.4 (20/82)	3.7 (1/27)	16.6 (64/385)	46.2 (6/13)	15.6 (58/372)	0.0036
Plasmapheresis	0 (0/266)	0 (0/50)	0 (0/87)	100 (27/27)	0 (0/403)	0 (0/13)	0 (0/390)	/
max.WHOscore(Median, IQR, available n)	5 (4-7), 266	7 (4-8), 50	6 (4-8), 83	7 (7-8), 27	6 (4-7), 399	8 (8-8), 13	6 (4-7), 386	0.0001
Outcome Discharged or transferred Deceased Unknown	81.0 (205/253) 19.0 (48/253) /	72.0 (36/50) 28.0 (14/50) /	72.0 (59/82) 25.6 (21/82) 2.4 (2/82)	51.8 (14/27) 48.2 (13/27) /	77.9 (300/385) 21.6 (83/385) 0.5 (2/385)	7.7 (1/13) 92.3 (12/13) /	80.4 (299/372) 19.1 (71/372) 0.5 (2/372)	0.0001

766 **Table 1: Baseline patient characteristics**

767 Data are shown in % (N/n) unless otherwise indicated.

768 IMV – invasive mechanical ventilation, IQR – interquartile range, CCI – Charlson's comorbidity index

769	Patients	with	DNI/DNR	were	excluded	for	IMV,	RRT,	ECMO,	and	Outcome
							,	,	_ • · · · • ,		

It is made available under a CC-BY-NC 4.0 International license . Akbil, Meyer, Stubbemann, Thibeault *et al.*

REFERENCES

- Abers, Michael S., Lindsey B. Rosen, Ottavia M. Delmonte, Elana Shaw, Paul Bastard, Luisa Imberti, Virginia Quaresima, et al. 2021. "Neutralizing Type-I Interferon Autoantibodies Are Associated with Delayed Viral Clearance and Intensive Care Unit Admission in Patients with COVID-19." *Immunology and Cell Biology*, July. https://doi.org/10.1111/imcb.12495.
- Ankerhold, Jakob, Sebastian Giese, Philipp Kolb, Andrea Maul-Pavicic, Reinhard E. Voll, Nathalie Göppert, Kevin Ciminski, et al. 2021. "Circulating Multimeric Immune Complexes Drive Immunopathology in COVID-19." *bioRxiv*. https://doi.org/10.1101/2021.06.25.449893.
- Bastard, Paul, Elizaveta Orlova, Leila Sozaeva, Romain Lévy, Alyssa James, Monica M. Schmitt, Sebastian Ochoa, et al. 2021. "Preexisting Autoantibodies to Type I IFNs Underlie Critical COVID-19 Pneumonia in Patients with APS-1." *The Journal of Experimental Medicine* 218 (7). https://doi.org/10.1084/jem.20210554.
- Bastard, Paul, Lindsey B. Rosen, Qian Zhang, Eleftherios Michailidis, Hans-Heinrich Hoffmann, Yu Zhang, Karim Dorgham, et al. 2020. "Autoantibodies against Type I IFNs in Patients with Life-Threatening COVID-19." *Science* 370 (6515). https://doi.org/10.1126/science.abd4585.
- Beccuti, G., L. Ghizzoni, V. Cambria, V. Codullo, P. Sacchi, E. Lovati, S. Mongodi, G. A. lotti, and F. Mojoli. 2020. "A COVID-19 Pneumonia Case Report of Autoimmune Polyendocrine Syndrome Type 1 in Lombardy, Italy: Letter to the Editor." *Journal of Endocrinological Investigation* 43 (8): 1175–77.
- Carpino, Andrea, Raffaele Buganza, Patrizia Matarazzo, Gerdi Tuli, Michele Pinon, Pier Luigi Calvo, Davide Montin, Francesco Licciardi, and Luisa De Sanctis. 2021. "Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy in Two Siblings: Same Mutations but Very Different Phenotypes." *Genes* 12 (2). https://doi.org/10.3390/genes12020169.
- Corman, Victor M., Olfert Landt, Marco Kaiser, Richard Molenkamp, Adam Meijer, Daniel Kw Chu, Tobias Bleicker, et al. 2020. "Detection of 2019 Novel Coronavirus (2019-nCoV) by Real-Time RT-PCR." *Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin* 25 (3). https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
- COVID-19 Host Genetics Initiative. 2021. "Mapping the Human Genetic Architecture of COVID-19." *Nature*, July. https://doi.org/10.1038/s41586-021-03767-x.
- Fernandez, Javier, Jordi Gratacos-Ginès, Pol Olivas, Montserrat Costa, Susana Nieto, Dolors Mateo, María Belén Sánchez, et al. 2020. "Plasma Exchange: An Effective Rescue Therapy in Critically III Patients With Coronavirus Disease 2019 Infection." *Critical Care Medicine* 48 (12): e1350–55.
- Ferré, Elise M. N., Monica M. Schmitt, Sebastian Ochoa, Lindsey B. Rosen, Elana R. Shaw, Peter D. Burbelo, Jennifer L. Stoddard, et al. 2021. "SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients." *Frontiers in Immunology* 12 (August): 720205.
- Goncalves, David, Mehdi Mezidi, Paul Bastard, Magali Perret, Kahina Saker, Nicole Fabien, Rémi Pescarmona, et al. 2021. "Antibodies against Type I Interferon: Detection and Association with Severe Clinical Outcome in COVID-19 Patients." *Clinical & Translational Immunology* 10 (8): e1327.
- Güven, Esin, Karen Duus, Magnus Christian Lydolph, Charlotte Sværke Jørgensen, Inga Laursen, and Gunnar Houen. 2014. "Non-Specific Binding in Solid Phase Immunoassays for Autoantibodies Correlates with Inflammation Markers." *Journal of Immunological Methods* 403 (1-2): 26–36.
- "Information on COVID-19 Treatment, Prevention and Research." n.d. Accessed September 25, 2021. https://www.covid19treatmentguidelines.nih.gov.

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

- Jones, Terry C., Guido Biele, Barbara Mühlemann, Talitha Veith, Julia Schneider, Jörn Beheim-Schwarzbach, Tobias Bleicker, et al. 2021. "Estimating Infectiousness throughout SARS-CoV-2 Infection Course." *Science* 373 (6551). https://doi.org/10.1126/science.abi5273.
- Kim, You-Me, and Eui-Cheol Shin. 2021. "Type I and III Interferon Responses in SARS-CoV-2 Infection." *Experimental & Molecular Medicine* 53 (5): 750–60.
- Knight, Stephen R., Antonia Ho, Riinu Pius, Iain Buchan, Gail Carson, Thomas M. Drake, Jake Dunning, et al. 2020. "Risk Stratification of Patients Admitted to Hospital with Covid-19 Using the ISARIC WHO Clinical Characterisation Protocol: Development and Validation of the 4C Mortality Score." *BMJ* 370 (September): m3339.
- Koning, Rutger, Paul Bastard, Jean-Laurent Casanova, Matthijs C. Brouwer, Diederik van de Beek, and with the Amsterdam U.M.C. COVID-19 Biobank Investigators. 2021.
 "Autoantibodies against Type I Interferons Are Associated with Multi-Organ Failure in COVID-19 Patients." *Intensive Care Medicine*.
- Kurth, F., M. Roennefarth, C. Thibeault, V. M. Corman, H. Muller-Redetzky, M. Mittermaier, C. Ruwwe-Glosenkamp, et al. 2020. "Studying the Pathophysiology of Coronavirus Disease 2019: A Protocol for the Berlin Prospective COVID-19 Patient Cohort (Pa-COVID-19)." *Infection* 48 (4): 619–26.
- Lemarquis, Andri, Tessa Campbell, Maribel Aranda-Guillén, Viktoria Hennings, Petter Brodin, Olle Kämpe, Kaj Blennow, et al. 2021. "Severe COVID-19 in an APS1 Patient with Interferon Autoantibodies Treated with Plasmapheresis." *The Journal of Allergy and Clinical Immunology* 148 (1): 96–98.
- Meisel, Christian, Bengisu Akbil, Tim Meyer, Erwin Lankes, Victor M. Corman, Olga Staudacher, Nadine Unterwalder, et al. 2021. "Mild COVID-19 despite Autoantibodies to Type I IFNs in Autoimmune-Polyendocrine-Syndrome Type 1 (APS-1)." *The Journal of Clinical Investigation*. https://www.jci.org/articles/view/150867.
- Meyer, Steffen, Martin Woodward, Christina Hertel, Philip Vlaicu, Yasmin Haque, Jaanika Kärner, Annalisa Macagno, et al. 2016. "AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies." *Cell* 166 (3): 582–95.
- Nusshag, Christian, Christian Morath, Claudius Speer, Florian Kaelble, Martin Zeier, Monica Boxberger, Elisa Schulze-Schleithoff, Mascha O. Fiedler, Markus A. Weigand, and Uta Merle. 2021. "Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience." *Critical Care Explorations* 3 (8): e0517.
- Okba, Nisreen M. A., Marcel A. Müller, Wentao Li, Chunyan Wang, Corine H. GeurtsvanKessel, Victor M. Corman, Mart M. Lamers, et al. 2020. "Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients." *Emerging Infectious Diseases* 26 (7): 1478–88.
- Pfortmueller, Carmen A., Thibaud Spinetti, Richard D. Urman, Markus M. Luedi, and Joerg C. Schefold. 2021. "COVID-19-Associated Acute Respiratory Distress Syndrome (CARDS): Current Knowledge on Pathophysiology and ICU Treatment - A Narrative Review." *Best Practice & Research. Clinical Anaesthesiology* 35 (3): 351–68.
- Prost, Nicolas de, Paul Bastard, Romain Arrestier, Slim Fourati, Mathieu Mahévas, Sonia Burrel, Karim Dorgham, et al. 2021. "Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia." *Journal of Clinical Immunology* 41 (3): 536–44.
- Sah, Pratha, Meagan C. Fitzpatrick, Charlotte F. Zimmer, Elaheh Abdollahi, Lyndon Juden-Kelly, Seyed M. Moghadas, Burton H. Singer, and Alison P. Galvani. 2021.
 "Asymptomatic SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis." *Proceedings of the National Academy of Sciences of the United States of America* 118 (34). https://doi.org/10.1073/pnas.2109229118.
- Sahud, M., O. Zhukov, K. Mo, J. Popov, and J. Dlott. 2012. "False-Positive Results in ELISA-Based Anti FVIII Antibody Assay May Occur with Lupus Anticoagulant and Phospholipid Antibodies." *Haemophilia: The Official Journal of the World Federation of Hemophilia* 18 (5): 777–81.
- Schwarz, Tatjana, Pinkus Tober-Lau, David Hillus, Elisa T. Helbig, Lena J. Lippert, Charlotte

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

Thibeault, Willi Koch, et al. 2021. "Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany." *Emerging Infectious Diseases* 27 (8): 2174–78.

- Spinetti, Thibaud, Cedric Hirzel, Michaela Fux, Laura N. Walti, Patrick Schober, Frank Stueber, Markus M. Luedi, and Joerg C. Schefold. 2020. "Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically III COVID-19 Patients." *Anesthesia and Analgesia* 131 (4): 993–99.
- Stuckrad, Sae Lim von, Jens Klotsche, Robert Biesen, Mareike Lieber, Julia Thumfart, Christian Meisel, Nadine Unterwalder, and Tilmann Kallinich. 2020. "SIGLEC1 (CD169) Is a Sensitive Biomarker for the Deterioration of the Clinical Course in Childhood Systemic Lupus Erythematosus." *Lupus* 29 (14): 1914–25.
- Troya, Jesús, Paul Bastard, Laura Planas-Serra, Pablo Ryan, Montse Ruiz, María de Carranza, Juan Torres, et al. 2021. "Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain." *Journal of Clinical Immunology*. https://doi.org/10.1007/s10875-021-01036-0.
- WHO Solidarity Trial Consortium, Hongchao Pan, Richard Peto, Ana-Maria Henao-Restrepo, Marie-Pierre Preziosi, Vasee Sathiyamoorthy, Quarraisha Abdool Karim, et al. 2021.
 "Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results." *The New England Journal of Medicine* 384 (6): 497–511.
- Wijst, Monique G. P. van der, Sara E. Vazquez, George C. Hartoularos, Paul Bastard, Tianna Grant, Raymund Bueno, David S. Lee, et al. 2021. "Type I Interferon Autoantibodies Are Associated with Systemic Immune Alterations in Patients with COVID-19." *Science Translational Medicine* 13 (612): eabh2624.
- Williamson, Elizabeth J., Alex J. Walker, Krishnan Bhaskaran, Seb Bacon, Chris Bates, Caroline E. Morton, Helen J. Curtis, et al. 2020. "Factors Associated with COVID-19-Related Death Using OpenSAFELY." *Nature* 584 (7821): 430–36.
- Wölfel, Roman, Victor M. Corman, Wolfgang Guggemos, Michael Seilmaier, Sabine Zange, Marcel A. Müller, Daniela Niemeyer, et al. 2020. "Virological Assessment of Hospitalized Patients with COVID-2019." *Nature* 581 (7809): 465–69.
- Zhang, Qian, Paul Bastard, Zhiyong Liu, Jérémie Le Pen, Marcela Moncada-Velez, Jie Chen, Masato Ogishi, et al. 2020. "Inborn Errors of Type I IFN Immunity in Patients with Life-Threatening COVID-19." *Science* 370 (6515). https://doi.org/10.1126/science.abd4570.
- Abers, Michael S., Lindsey B. Rosen, Ottavia M. Delmonte, Elana Shaw, Paul Bastard, Luisa Imberti, Virginia Quaresima, et al. 2021. "Neutralizing Type-I Interferon Autoantibodies Are Associated with Delayed Viral Clearance and Intensive Care Unit Admission in Patients with COVID-19." Immunology and Cell Biology, July. https://doi.org/10.1111/imcb.12495.
- Bastard, Paul, Elizaveta Orlova, Leila Sozaeva, Romain Lévy, Alyssa James, Monica M. Schmitt, Sebastian Ochoa, et al. 2021. "Preexisting Autoantibodies to Type I IFNs Underlie Critical COVID-19 Pneumonia in Patients with APS-1." The Journal of Experimental Medicine 218 (7). https://doi.org/10.1084/jem.20210554.
- Bastard, Paul, Lindsey B. Rosen, Qian Zhang, Eleftherios Michailidis, Hans-Heinrich Hoffmann, Yu Zhang, Karim Dorgham, et al. 2020. "Autoantibodies against Type I IFNs in Patients with Life-Threatening COVID-19." Science 370 (6515). https://doi.org/10.1126/science.abd4585.
- Beccuti, G., L. Ghizzoni, V. Cambria, V. Codullo, P. Sacchi, E. Lovati, S. Mongodi, G. A. lotti, and F. Mojoli. 2020. "A COVID-19 Pneumonia Case Report of Autoimmune Polyendocrine Syndrome Type 1 in Lombardy, Italy: Letter to the Editor." Journal of Endocrinological Investigation 43 (8): 1175–77.
- Carpino, Andrea, Raffaele Buganza, Patrizia Matarazzo, Gerdi Tuli, Michele Pinon, Pier Luigi Calvo, Davide Montin, Francesco Licciardi, and Luisa De Sanctis. 2021. "Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy in Two Siblings: Same Mutations but Very Different Phenotypes." Genes 12 (2). https://doi.org/10.3390/genes12020169.

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

- Corman, Victor M., Olfert Landt, Marco Kaiser, Richard Molenkamp, Adam Meijer, Daniel Kw Chu, Tobias Bleicker, et al. 2020. "Detection of 2019 Novel Coronavirus (2019-nCoV) by Real-Time RT-PCR." Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 25 (3). https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
- COVID-19 Host Genetics Initiative. 2021. "Mapping the Human Genetic Architecture of COVID-19." Nature, July. https://doi.org/10.1038/s41586-021-03767-x.
- Fernandez, Javier, Jordi Gratacos-Ginès, Pol Olivas, Montserrat Costa, Susana Nieto, Dolors Mateo, María Belén Sánchez, et al. 2020. "Plasma Exchange: An Effective Rescue Therapy in Critically III Patients With Coronavirus Disease 2019 Infection." Critical Care Medicine 48 (12): e1350–55.
- Ferré, Elise M. N., Monica M. Schmitt, Sebastian Ochoa, Lindsey B. Rosen, Elana R. Shaw, Peter D. Burbelo, Jennifer L. Stoddard, et al. 2021. "SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients." Frontiers in Immunology 12 (August): 720205.
- Goncalves, David, Mehdi Mezidi, Paul Bastard, Magali Perret, Kahina Saker, Nicole Fabien, Rémi Pescarmona, et al. 2021. "Antibodies against Type I Interferon: Detection and Association with Severe Clinical Outcome in COVID-19 Patients." Clinical & Translational Immunology 10 (8): e1327.
- Güven, Esin, Karen Duus, Magnus Christian Lydolph, Charlotte Sværke Jørgensen, Inga Laursen, and Gunnar Houen. 2014. "Non-Specific Binding in Solid Phase Immunoassays for Autoantibodies Correlates with Inflammation Markers." Journal of Immunological Methods 403 (1-2): 26–36.
- "Information on COVID-19 Treatment, Prevention and Research." n.d. Accessed September 25, 2021. https://www.covid19treatmentguidelines.nih.gov.
- Jones, Terry C., Guido Biele, Barbara Mühlemann, Talitha Veith, Julia Schneider, Jörn Beheim-Schwarzbach, Tobias Bleicker, et al. 2021. "Estimating Infectiousness throughout SARS-CoV-2 Infection Course." Science 373 (6551). https://doi.org/10.1126/science.abi5273.
- Kim, You-Me, and Eui-Cheol Shin. 2021. "Type I and III Interferon Responses in SARS-CoV-2 Infection." Experimental & Molecular Medicine 53 (5): 750–60.
- Knight, Stephen R., Antonia Ho, Riinu Pius, Iain Buchan, Gail Carson, Thomas M. Drake, Jake Dunning, et al. 2020. "Risk Stratification of Patients Admitted to Hospital with Covid-19 Using the ISARIC WHO Clinical Characterisation Protocol: Development and Validation of the 4C Mortality Score." BMJ 370 (September): m3339.
- Koning, Rutger, Paul Bastard, Jean-Laurent Casanova, Matthijs C. Brouwer, Diederik van de Beek, and with the Amsterdam U.M.C. COVID-19 Biobank Investigators. 2021.
 "Autoantibodies against Type I Interferons Are Associated with Multi-Organ Failure in COVID-19 Patients." Intensive Care Medicine.
- Lemarquis, Andri, Tessa Campbell, Maribel Aranda-Guillén, Viktoria Hennings, Petter Brodin, Olle Kämpe, Kaj Blennow, et al. 2021. "Severe COVID-19 in an APS1 Patient with Interferon Autoantibodies Treated with Plasmapheresis." The Journal of Allergy and Clinical Immunology 148 (1): 96–98.
- Meisel, Christian, Bengisu Akbil, Tim Meyer, Erwin Lankes, Victor M. Corman, Olga Staudacher, Nadine Unterwalder, et al. 2021. "Mild COVID-19 despite Autoantibodies to Type I IFNs in Autoimmune-Polyendocrine-Syndrome Type 1 (APS-1)." The Journal of Clinical Investigation. https://www.jci.org/articles/view/150867.
- Meyer, Steffen, Martin Woodward, Christina Hertel, Philip Vlaicu, Yasmin Haque, Jaanika Kärner, Annalisa Macagno, et al. 2016. "AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies." Cell 166 (3): 582–95.
- Nusshag, Christian, Christian Morath, Claudius Speer, Florian Kaelble, Martin Zeier, Monica Boxberger, Elisa Schulze-Schleithoff, Mascha O. Fiedler, Markus A. Weigand, and Uta Merle. 2021. "Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience." Critical Care Explorations 3 (8): e0517.
- Okba, Nisreen M. A., Marcel A. Müller, Wentao Li, Chunyan Wang, Corine H.

It is made available under a CC-BY-NC 4.0 International license .

Akbil, Meyer, Stubbemann, Thibeault et al.

GeurtsvanKessel, Victor M. Corman, Mart M. Lamers, et al. 2020. "Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients." Emerging Infectious Diseases 26 (7): 1478–88.

- Prost, Nicolas de, Paul Bastard, Romain Arrestier, Slim Fourati, Mathieu Mahévas, Sonia Burrel, Karim Dorgham, et al. 2021. "Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia." Journal of Clinical Immunology 41 (3): 536–44.
- Sahud, M., O. Zhukov, K. Mo, J. Popov, and J. Dlott. 2012. "False-Positive Results in ELISA-Based Anti FVIII Antibody Assay May Occur with Lupus Anticoagulant and Phospholipid Antibodies." Haemophilia: The Official Journal of the World Federation of Hemophilia 18 (5): 777–81.
- Schwarz, Tatjana, Pinkus Tober-Lau, David Hillus, Elisa T. Helbig, Lena J. Lippert, Charlotte Thibeault, Willi Koch, et al. 2021. "Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany." Emerging Infectious Diseases 27 (8): 2174–78.
- Spinetti, Thibaud, Cedric Hirzel, Michaela Fux, Laura N. Walti, Patrick Schober, Frank Stueber, Markus M. Luedi, and Joerg C. Schefold. 2020. "Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically III COVID-19 Patients." Anesthesia and Analgesia 131 (4): 993–99.
- Stuckrad, Sae Lim von, Jens Klotsche, Robert Biesen, Mareike Lieber, Julia Thumfart, Christian Meisel, Nadine Unterwalder, and Tilmann Kallinich. 2020. "SIGLEC1 (CD169) Is a Sensitive Biomarker for the Deterioration of the Clinical Course in Childhood Systemic Lupus Erythematosus." Lupus 29 (14): 1914–25.
- Troya, Jesús, Paul Bastard, Laura Planas-Serra, Pablo Ryan, Montse Ruiz, María de Carranza, Juan Torres, et al. 2021. "Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain." Journal of Clinical Immunology. https://doi.org/10.1007/s10875-021-01036-0.
- WHO Solidarity Trial Consortium, Hongchao Pan, Richard Peto, Ana-Maria Henao-Restrepo, Marie-Pierre Preziosi, Vasee Sathiyamoorthy, Quarraisha Abdool Karim, et al. 2021.
 "Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results." The New England Journal of Medicine 384 (6): 497–511.
- Wijst, Monique G. P. van der, Sara E. Vazquez, George C. Hartoularos, Paul Bastard, Tianna Grant, Raymund Bueno, David S. Lee, et al. 2021. "Type I Interferon Autoantibodies Are Associated with Systemic Immune Alterations in Patients with COVID-19." Science Translational Medicine 13 (612): eabh2624.
- Williamson, Elizabeth J., Alex J. Walker, Krishnan Bhaskaran, Seb Bacon, Chris Bates, Caroline E. Morton, Helen J. Curtis, et al. 2020. "Factors Associated with COVID-19-Related Death Using OpenSAFELY." Nature 584 (7821): 430–36.
- Wölfel, Roman, Victor M. Corman, Wolfgang Guggemos, Michael Seilmaier, Sabine Zange, Marcel A. Müller, Daniela Niemeyer, et al. 2020. "Virological Assessment of Hospitalized Patients with COVID-2019." Nature 581 (7809): 465–69.
- Zhang, Qian, Paul Bastard, Zhiyong Liu, Jérémie Le Pen, Marcela Moncada-Velez, Jie Chen, Masato Ogishi, et al. 2020. "Inborn Errors of Type I IFN Immunity in Patients with Life-Threatening COVID-19." Science 370 (6515). https://doi.org/10.1126/science.abd4570.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.12.21266249; this version posted November 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC 4.0 International license .



Competition Assay



medRxiv preprint doi: https://doi.org/10.1101/2021.11.12.21266249; this version posted November 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.



medRxiv preprint doi: https://doi.org/10.1101/2021.11.12.21266249; this version posted November 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.



medRxiv preprint doi: https://doi.org/10.1101/2021.11.12.21266249; this version posted November 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.



medRxiv preprint doi: https://doi.org/10.1101/2021.11.12.21266249; this version posted November 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.



medRxiv preprint doi: https://doi.org/10.1101/2021.11.12.21266249; this version posted November 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.



medRxiv preprint doi: https://doi.org/10.1101/2021.11.12.21266249; this version posted November 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Sars-CoV-2 infected patients KA MA 2 0 2 0

0

0

